Results from the single-arm open-label trial have been able to elicit an extension of CD34+ cells ex vivo in two out of the 12 patients enrolled on the trial. The trial data, published in the New ...

In the study, "Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A," published in The New England Journal of Medicine, researchers used a lentiviral vector to deliver gene ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

Pain and clinical scores were calculated for each patient. Image analysis to calculate area percent for TLR-2 and CD34 immuno-expression was performed. Data was tabulated and statistically analyzed.

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced it will be presenting next week at Terrapinn’s Advanced Therapies Congress 2025, held in London. Ibon ...

With gene therapy, CD34+ cells can produce fetal haemoglobin, which then takes over from the faulty version. Yen carries out in vivo pharmacology and toxicology studies on these therapies in mice ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...